GSK will clinch the deal to buy Amarin soon--Canaccord knows something
Canaccord analyst knows something about acquisition of Amarin.
GSK is desperate--will clinch the "BINDING DEAL" soon.
Private investment co.that have Directors on Amarin's board also want to make money quickly.
Joe Zakrzewski--will have to settle with a deal in 25-30$ range .
I also think Bloomberg will get the scoop from a source soon as they did for Amylin inApril,2012 if the deal bid is below 25$/share. Amylin reported a bid by BMY for 22$--final deal in July was 31$/share.
AMRN is worthless and is laughed at by serious players. GSK are under a contract with PRON and can't buy AMRN even if they wanted to. But why would they want a worthless decades old Jpanese fish-oil that is inferior to their own Lovaza?
GSK will make far more money from Lovaza than Vascepa WITH generic Lovaza on the market from 2015!
Contracts are broken. American Home Product(Wyeth) had binding deal with Warner Lambert in 1999--knowing fully well Pfizer's 10 year marketing contact with WL.
These contracts can be broken for some settlement cost which could be 2 years royalty payment to Pronova.